Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles.
Tumour-targeted delivery of therapeutic agents is a longstanding pharmacological goal to improve selectivity and Therapeutic Index. Most scientists have sought to use 'active' receptor-mediated tumour-targeting systems, however the 'passive' targeting afforded by the Enhanced Permeability and Retention (EPR) effects provides a versatile and non-saturable opportunity for tumour-selective delivery. Polymeric micelles are ideally suited to exploit the EPR effect, and they have been used for the delivery of a range of anticancer drugs in preclinical and clinical studies. Here I overview some of the more important approaches, assessing usefulness and seeking to identify the most promising ways to apply the phenomenon of passive targeting for improved clinical outcome.
Matsumura
Yasuhiro
Y
Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Chiba, Japan.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008823:Micelles; D009369:Neoplasms / Q000188:drug therapy*; D010539:Permeability; D011108:Polymers / Q000737:chemistry
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008823:Micelles; D011108:Polymers